Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity

被引:32
作者
Chong, H
Hutchinson, G
Hart, IR
Vile, RG
机构
[1] ST THOMAS HOSP,RAYNE INST,IMPERIAL CANC RES FUND,LAB CANC GENE THERAPY,LONDON SE1 7EH,ENGLAND
[2] ST THOMAS HOSP,RAYNE INST,ICRF LAB,RICHARD DIMBLEBY DEPT CANC RES,LONDON SE1 7EH,ENGLAND
关键词
D O I
10.1089/hum.1996.7.14-1771
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Many tumor cells do not express co-stimulatory molecules, and this may account, in part, for their poor ability to stimulate T cells directly, One strategy to enhance immune recognition would be to express such molecules on the tumor cell, Here, we show that expression of a member of the B7 family of co-stimulatory molecules by CMT93 murine colorectal tumor or 1735 murine melanoma cells resulted in a local antitumor response in immunocompetent mice, The antitumor effect was diminished in athymic nude mice, indicating that T cells played an important part in this response, The ability of the B7-expressing tumor cells to generate systemic protective immunity was investigated by excision of tumors that developed from the initial inoculation followed by rechallenge with parental tumor cells, CMT93 is a poorly immunogenic tumor and no significant systemic immunity was elicited by the expression of B7-1 in these cells, 1735 melanoma is a mildly immunogenic tumor, Unexpectedly, the systemic immunity obtained with 1735 tumors expressing B7-1 or B7-2 was weaker than that generated by parental 1735 cells (p < 0.001, stratified logrank test), even when coexpression of interferon-gamma in the B7-1 cells produced high levels of surface MHC class I expression, These results suggest that some caution is appropriate when considering the use of these molecules in the gene therapy of cancer.
引用
收藏
页码:1771 / 1779
页数:9
相关论文
共 55 条
[1]  
ALLIONE A, 1994, CANCER RES, V54, P6022
[2]  
Altman DG., 1991, PRACTICAL STAT MED R
[3]   CD28 INTERACTION WITH B7-COSTIMULATES PRIMARY ALLOGENEIC PROLIFERATIVE RESPONSES AND CYTOTOXICITY MEDIATED BY SMALL, RESTING LYMPHOCYTES-T [J].
AZUMA, M ;
CAYABYAB, M ;
BUCK, D ;
PHILLIPS, JH ;
LANIER, LL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :353-360
[4]   B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28 [J].
AZUMA, M ;
ITO, D ;
YAGITA, H ;
OKUMURA, K ;
PHILLIPS, JH ;
LANIER, LL ;
SOMOZA, C .
NATURE, 1993, 366 (6450) :76-79
[5]   MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II(+)B7-1(+) TUMOR-CELLS ARE POTENT VACCINES FOR STIMULATING TUMOR REJECTION IN TUMOR-BEARING MICE [J].
BASKAR, S ;
GLIMCHER, L ;
NABAVI, N ;
JONES, RT ;
OSTRANDROSENBERG, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (02) :619-629
[6]   NEW PERSPECTIVES OF CD28-B7-MEDIATED T-CELL COSTIMULATION [J].
BLUESTONE, JA .
IMMUNITY, 1995, 2 (06) :555-559
[7]  
BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
[8]   TUMOR-CELLS COTRANSFECTED WITH INTERLEUKIN-7 AND B7.1 GENES INDUCE CD25 AND CD28 ON TUMOR-INFILTRATING T-LYMPHOCYTES AND ARE STRONG VACCINES [J].
CAYEUX, S ;
BECK, C ;
AICHER, A ;
DORKEN, B ;
BLANKENSTEIN, T .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (08) :2325-2331
[9]   TUMOR IMMUNOGENICITY DETERMINES THE EFFECT OF B7 COSTIMULATION ON T-CELL-MEDIATED TUMOR-IMMUNITY [J].
CHEN, LP ;
MCGOWAN, P ;
ASHE, S ;
JOHNSTON, J ;
LI, YW ;
HELLSTROM, I ;
HELLSTROM, KE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :523-532
[10]   COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4 [J].
CHEN, LP ;
ASHE, S ;
BRADY, WA ;
HELLSTROM, I ;
HELLSTROM, KE ;
LEDBETTER, JA ;
MCGOWAN, P ;
LINSLEY, PS .
CELL, 1992, 71 (07) :1093-1102